Get the Daily Brief
Latest Biotech News
Cancer Biology: Tumor Microenvironment and Metastasis Mechanisms
Groundbreaking research is unraveling complex interactions within the tumor microenvironment. The protein SPON2 has been identified as a driver of osteosarcoma progression via M2 macrophage...
Breakthroughs in Epigenetics and Immune Dysregulation in Disease
Recent proteomic and epigenomic studies are redefining pathophysiological understanding in cancer and neurodegeneration. A Nature Communications paper reveals autocrine interferon signaling...
Gene Editing Advances Powered by AI: CRISPR Automation and AI-Designed Therapeutics
Artificial intelligence is increasingly integrated into gene editing technologies. The innovative CRISPR-GPT system automates design and conduct of gene-editing experiments through large language...
Regulatory and Market Trends: Biotech Financial Moves and Leadership Changes
The biotech industry is witnessing significant financial and leadership developments. Novo Nordisk named Mike Doustdar as incoming CEO amid a sharp downgrade of sales forecasts for its obesity...
Cancer Diagnostic and Therapeutic Innovations
Several companies have reported advancements in cancer diagnostics and treatments. Saga Diagnostics achieved Medicare coverage for its Pathlight molecular residual disease test for breast cancer...
Innovations in Rare Disease and Genetic Therapeutics
Recent advances in gene and cell therapies include FDA approvals and promising trial results. PTC Therapeutics obtained FDA approval for Sephience, an oral therapy for phenylketonuria, expanding...
Environmental and Agricultural Innovations
Research teams have developed transformative technologies for environmental and agricultural applications. Carnegie Mellon University scientists employed AI-generated synthetic images to enhance...
FDA Reverses Course on Sarepta’s Duchenne Therapy Amid Safety Review
The FDA has permitted Sarepta Therapeutics to resume shipments of its gene therapy Elevidys for ambulatory patients with Duchenne muscular dystrophy (DMD) following an investigation that concluded...
Novo Nordisk Cuts Sales Forecast, Names New CEO amid Obesity Drug Pressure
Novo Nordisk has substantially lowered its 2025 sales growth expectations for its obesity and diabetes treatment portfolio, including GLP-1 agonists Ozempic and Wegovy, citing increased...
Apellis Pharmaceuticals Expands Empaveli Approval for Rare Kidney Diseases
Apellis Pharmaceuticals received FDA approval to broaden the labeling of its complement C3 inhibitor, Empaveli (pegcetacoplan), for treatment of complement 3 glomerulopathy (C3G) and primary...
Bristol Myers Squibb Spins Off Immunology Drugs in $300M Bain-Backed Startup
Bristol Myers Squibb is divesting five immune-modulating drug candidates, including three already in clinical development, to a newly formed biotech company financed with $300 million led by Bain...
Merck Plans $3 Billion Cost Cuts with Strategic Focus Shift to New Drugs
Facing declining revenue from blockbuster products like Keytruda and Gardasil, Merck announced an ambitious $3 billion annual cost-saving program to be completed by 2027. The initiative includes...
GeneDx Reports 49% Revenue Growth Fueled by Genome and Exome Testing Expansion
GeneDx, a genetic diagnostics company, announced a 49% year-over-year revenue increase in Q2 2025, totaling $102.7 million and marking its fourth consecutive profitable quarter. Growth is...
AI-Powered ‘Virtual Labs’ Mimic Scientific Collaboration for Research Acceleration
Researchers from Stanford University and the Chan Zuckerberg Biohub developed a novel AI-based ‘Virtual Lab,’ where multiple specialized AI agents collaborate, simulating multidisciplinary...
CRISPR-GPT and AI Enhance Gene Editing Experiment Design
An interdisciplinary team from Stanford, Princeton, Google DeepMind, and UC Berkeley introduced CRISPR-GPT, an AI system combining large language models with expert knowledge to automate design...
Madrigal Pharmaceuticals Secures $2 Billion Deal for Preclinical GLP-1 Agonist
Madrigal Pharmaceuticals entered an exclusive global licensing agreement with China-based CSPC Pharmaceutical Group for SYH-2086, a preclinical oral small-molecule GLP-1 receptor agonist. The deal...
Expansion and Innovations in Cell and Gene Therapy Manufacturing at Academic Centers
Academic institutions like Roswell Park Comprehensive Cancer Center are significantly scaling in-house clinical-grade cell manufacturing facilities, enabling higher throughput and tighter...
FDA Shifts After Sarepta Gene Therapy Controversy
The FDA has reversed its earlier halt on Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy, allowing shipments to ambulatory patients to resume after investigations found...
Merck’s Strategic Cost-Cutting and Priorities Shift
Merck announced a $3 billion annual cost reduction plan by 2027 to redirect investments into newly launched and pipeline drugs across oncology and cardiometabolic areas ahead of upcoming...
Novo Nordisk’s Leadership and Financial Update in Obesity Market
Novo Nordisk appointed Mike Doustdar as its new CEO amid lowered financial guidance for 2025, cutting expected sales growth of blockbuster obesity and diabetes drugs Wegovy and Ozempic to 8–14%...